Current Issues in the Staging of Esophageal Cancer.

Semin Radiat Oncol

Division of Thoracic Surgery, Brigham and Women' Hospital, Boston, MA, USA

Published: July 1994

Staging technology and the 1983 international staging system for esophageal cancer have changed. The 1988 system is based on depth of wall penetration and regional lymph node involvement; it abandons the previous criteria of tumor length and degree of obstruction. The clinical reasoning behind this change is reviewed. New staging technology includes chest computed tomography (CT), magnetic resonance imaging (MRI), tranesophageal ultrasound (EUS), and invasive surgical staging. Overall accuracy of CT to predict depth of penetration is 80% to 85%. CT accuracy of regional lymph node status is less than 69%, but it is 90% accurate in the detection of distant metastases. MRI is comparable. EUS is 71% to 98% accurate in predicting depth of tumor invasion. Although highly sensitive (85% to 95%), the accuracy of EUS in predicting the status of lymph nodes is adversely affected by low specificity (50% to 60%), reducing its overall accuracy of node prediction to 70% to 88%. EUS may fail to assess intra-abdominal disease in 21% to 36% of patients secondary to esophageal obstruction. Regional nodes on both sides of the diaphragm can be assessed by laparoscopy combined with thoracoscopy. Thoracoscopy and laparoscopy have a greater than 92% accuracy in staging regional nodes. Such information is indispensable for the design of treatment fields. Combinations of these new technologies may provide improved preresectional staging.

Download full-text PDF

Source
http://dx.doi.org/10.1053/SRAO00400135DOI Listing

Publication Analysis

Top Keywords

esophageal cancer
8
staging technology
8
regional lymph
8
lymph node
8
regional nodes
8
staging
7
accuracy
5
current issues
4
issues staging
4
staging esophageal
4

Similar Publications

This study aims to investigate the expression of GPER in EC, assess the impact of estrogen on the proliferation and migration of EC via GPER, and examine the potential role of GPER in mediating the NOTCH pathway to influence EC proliferation and migration. The expression of GPER and its correlation with clinicopathological features were investigated using clinical data. Cell proliferation was assessed through MTT and EdU assays, while cell migration ability was evaluated using wound healing and transwell assays.

View Article and Find Full Text PDF

The P2YR is activated by UDP and UDP glucose and is involved in many human inflammatory diseases. Based on the molecular docking analysis of currently reported P2YR antagonists and the crystallographic overlap study between PPTN and compound , a series of 3-substituted 5-amidobenzoate derivatives were designed, synthesized, and identified as promising P2YR antagonists. The optimal compound (methyl 3-(1-benzo[]imidazol-2-yl)-5-(2-(-tolyl) acetamido)benzoate, IC = 0.

View Article and Find Full Text PDF

Background: The relationship between patient nutritional, immune, and inflammatory status is linked to tumor progression and prognosis. However, there are limited studies on the prognosis of esophageal squamous cell carcinoma (ESCC) after surgery based on the comprehensive indicators of these factors.

Aim: To develop and validate a novel nomogram based on a nutritional immune-inflammatory status (NIIS) score for predicting postoperative outcomes in ESCC.

View Article and Find Full Text PDF

Nivolumab has been approved for unresectable recurrent advanced esophageal cancer. The present study aimed to provide real-world data on diverse patient profiles, including the elderly and those with poor performance status, while exploring therapeutic efficacy biomarkers. This retrospective study included 42 patients with esophageal cancer who received nivolumab after second- or later-line treatment at Kyoto Prefectural University of Medicine (Kyoto, Japan) from February 2020 to December 2021.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!